Viatris Inc (VTRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1117)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Nächster Verdiensttermin

Neueste SEC-Einreichungen

VTRS's Discussions on Twitter

Vergleichen Sie VTRS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VTRS Viatris Inc	12.66	14.51B	14.33B	-3.79B	1.84B	-3.17
ZTS Zoetis Inc	126.35	55.90B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	16.33	51.72B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.92	44.71B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	32.07	37.30B	16.88B	666.71M	251.19M	0.6132
RGC Regencell Bioscience Holdings Ltd	50.30	20.48B	0	-5.87M	-767.30K	-0.45

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-15	Eingeleitet	Truist	Buy
2025-06-06	Eingeleitet	Goldman	Neutral
2024-07-19	Fortgesetzt	Jefferies	Buy
2023-10-23	Herabstufung	BofA Securities	Neutral → Underperform
2023-06-23	Herabstufung	Barclays	Equal Weight → Underweight
2023-04-24	Herabstufung	Barclays	Overweight → Equal Weight
2023-02-17	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Hochstufung	Jefferies	Hold → Buy
2022-11-10	Hochstufung	UBS	Sell → Neutral
2022-11-08	Hochstufung	Piper Sandler	Underweight → Neutral
2022-10-21	Fortgesetzt	Jefferies	Hold
2022-06-14	Eingeleitet	UBS	Sell
2022-05-10	Herabstufung	Piper Sandler	Neutral → Underweight
2022-03-01	Herabstufung	BofA Securities	Buy → Neutral
2022-03-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-06-15	Eingeleitet	Citigroup	Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-03-08	Herabstufung	Goldman	Buy → Neutral
2021-03-02	Herabstufung	JP Morgan	Overweight → Neutral
2021-02-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2021-01-05	Eingeleitet	Argus	Hold
2020-12-14	Eingeleitet	Bernstein	Mkt Perform

Alle ansehen

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Finanzdaten der Viatris Inc-Aktie (VTRS)

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Vergleichen Sie VTRS mit anderen Aktien

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Can Viatris Inc. stock deliver strong Q4 earningsTrend Reversal & Growth Focused Entry Point Reports - ulpravda.ru

How analysts revise price targets for Viatris Inc. (VIA) stockCPI Data & High Conviction Investment Ideas - ulpravda.ru

Does Viatris Inc. (VIA) stock trade below intrinsic value2025 Historical Comparison & Real-Time Volume Trigger Notifications - ulpravda.ru

Performance Recap: Why Viatris Inc. stock remains on buy listsMarket Activity Report & Safe Entry Zone Identification - ulpravda.ru

Viatris names veteran executive to lead people and corporate affairs - The Business Journals

Viatris stock hits 52-week high at 12.68 USD By Investing.com - Investing.com South Africa

Why Viatris Inc. stock remains on buy listsEarnings Trend Report & AI Powered Trade Plan Recommendations - ulpravda.ru

Viatris appoints Lara Ramsburg as chief people and corporate affairs officer - MarketScreener

Viatris names Lara Ramsburg as chief people and corporate affairs officer - Investing.com Australia

Viatris names Lara Ramsburg as chief people and corporate affairs officer By Investing.com - Investing.com South Africa

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer - Viatris

Viatris Inc.: How a Quiet Generic Drug Giant Is Re?wiring Global Healthcare - AD HOC NEWS

Barclays initiates Viatris (VTRS) with overweight as pharma sentiment improves - MSN

Is Viatris stock outperforming the Dow? - MSN

Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Taxanes Market to Reach US$ 8.67 Billion by 2032 at 10.73% CAGR; - openPR.com

1 Healthcare Stock to Target This Week and 2 We Turn Down - FinancialContent

A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones - Yahoo Finance

Anti-Depression Drugs Market to Reach USD 22.10 Billion by 2031 | - openPR.com

Viatris Inc.: Can a Hybrid Pharma Powerhouse Redefine Global Generics and Biosimilars? - AD HOC NEWS

Take Profit: Will Viatris Inc stock outperform Nasdaq indexJuly 2025 Setups & Verified Chart Pattern Signals - moha.gov.vn

Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones - Finviz

Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus

Viatris stock hits 52-week high at $12.60 By Investing.com - Investing.com Nigeria

Viatris stock hits 52-week high at $12.60 - Investing.com India

Viatris Inc. stock rises Wednesday, outperforms market - MSN

Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves - Insider Monkey

Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch

Viatris Inc. (VTRS) Stock Analysis: Navigating a 3.90% Dividend Yield Amidst Challenging Metrics - DirectorsTalk Interviews

Viatris Inc. Stock Climbs 1.8%, Outperforms Market - 富途牛牛

Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025 - FinancialContent

How Is The Market Feeling About Viatris Inc?Viatris (NASDAQ:VTRS) - Benzinga

Viatris: Looks Cheap, But Faces Continued Contraction (NASDAQ:VTRS) - Seeking Alpha

Wall Street Recap: How strong is Viatris Inc. stock revenue growthStock Surge & Safe Capital Growth Trade Ideas - moha.gov.vn

Earnings Risk: How Viatris Inc. (VIA) stock trades after earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru

Is Viatris’ Shift Into Complex Therapies Altering The Investment Case For VTRS? - Yahoo Finance

Viatris (VTRS): Reassessing Valuation After Recent Share Price Gains and Evolving Investor Sentiment - Yahoo Finance

Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks

Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates - Yahoo News Malaysia

Is Viatris Inc. stock safe for conservative investorsEarnings Miss & Fast Moving Stock Watchlists - DonanımHaber

Viatris’ MR-146 gains IND clearance for neurotrophic keratopathy - BioWorld MedTech

Viatris secures four regulatory milestones across global pipeline By Investing.com - Investing.com Australia

Will Viatris Inc. stock outperform Nasdaq index2025 Valuation Update & Verified Technical Trade Signals - DonanımHaber

Viatris Provides Pipeline Update on Four Regulatory Milestones - The Malaysian Reserve

Update Recap: How Viatris Inc. stock valuations compare to rivalsWeekly Market Report & Fast Entry Momentum Alerts - Улправда

Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson - PharmiWeb.com

Viatris racks up regulatory wins across therapy areas - The Pharma Letter

Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials - marketscreener.com

Rally Mode: How Viatris Inc VIA stock behaves in tightening cyclesQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - moha.gov.vn

Viatris secures four regulatory milestones across global pipeline - Investing.com

Finanzdaten der Viatris Inc-Aktie (VTRS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie VTRS